Abstract In recent years, there has been heightened scrutiny of potential contaminants in cannabis, ranging from pesticides and chemical fertilizers to heavy metals and biological hazards. Among these, the presence…
Medicinal cannabis use is at an all-time high in the United States. From 2016 to 2020 alone, the number of patients enrolled in a state medical marijuana program quadrupled, according…
As the DEA proposes moving cannabis to Schedule III of the Controlled Substances Act, we enter a transformative period in the understanding and utilization of this complex botanical product. Moving…
On April 30th, 2024, the DEA accepted the recommendation of the U.S. Health and Human Services and FDA that cannabis should be reclassified as a Schedule 3 drug along with…
The State of Connecticut, Office of the Healthcare Advocate (OHA) is recruiting for a Cannabis Ombudsperson position in Hartford, CT. They are seeking a professional who is familiar with the…
Dr. Shiksha Gallow, one of the Board members of the SCC, was invited as one of the global keynote speakers at the Asia International Hemp and Cannabis Forum in Bangkok,…
Does Cannabis Cause Heart Failure and Stroke? You may have seen the recent headlines about two new studies that found “marijuana use raises risk of heart attack, heart failure and…
SCC Member, Dave Gordon MD, was recently invited to review a middle school cannabis curriculum. Read below to see how education for this population has evolved since the DARE Program days.
It is with great honor and pride that we share that our SCC Board Member, Dr. Patricia Frye, on the 17th of May 2023, gave the Commencement Ceremony to the…
Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2–3 weeks or more. In the clinic, the speed of beginning of the actions of antidepressant drugs or other interventions is vital for many reasons.
Preclinical models provided ample evidence that cannabinoids are cytotoxic against cancer cells. Among the best studied phytocannabinoids, cannabidiol (CBD) is most promising for the treatment of cancer as it lacks the psychotomimetic properties of delta-9-tetrahydrocannabinol (THC).
Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological and psychological responses to aerobic exercise to determine its practical utility within the sporting context.